Microenvironment-activatable cascaded responsive carbonized polymer dots as a theranostic platform for precise rapamycin delivery to potentiate the synergy of chemotherapy and γδ T cells-mediated immunotherapy against tumor
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Immune Cell Function and Interaction · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Emerging concepts for immune checkpoint blockade-based combination therapies10.1016/j.ccell.2018.03.005 ↗
2. Chimeric antigen receptor therapy for cancer10.1146/annurev-med-060512-150254 ↗
3. γδT cells–Pleiotropic immune effectors with therapeutic potential in cancer10.1038/s41568-019-0153-5 ↗
4. γδT cells–First line of defense and beyond10.1146/annurev-immunol-032713-120216 ↗
5. The multifunctionality of human Vγ9Vδ2 γδT cells–Clonal plasticity or distinct subsets?10.1111/j.1365-3083.2012.02727.x ↗
6. Role of gamma-delta (γδ) T cells in autoimmunity10.1189/jlb.3RU0914-443R ↗
7. The role of the γδT cell in allergic diseases10.1155/2014/963484 ↗
8. Gamma-delta (γδ) T cells–Friend or foe in cancer development?10.1186/s12967-017-1378-2 ↗
9. Lysis of a broad range of epithelial tumour cells by human γδT cells–Involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition10.1111/j.1365-3083.2007.01963.x ↗
10. Regulation of ligands for the NKG2D activating receptor10.1146/annurev-immunol-032712-095951 ↗
11. Roles of the NKG2D immunoreceptor and its ligands10.1038/nri1199 ↗
12. Advances in NKG2D ligand recognition and responses by NK cells10.1038/icb.2013.111 ↗
13. mTOR inhibition potentiates cytotoxicity of Vγ4 γδT cells via up-regulating NKG2D and TNF-α10.1189/jlb.5A0116-053RR ↗
14. mTOR-targeted therapy of cancer with rapamycin derivatives10.1093/annonc/mdi113 ↗
15. Cancer nanomedicine for combination cancer immunotherapy10.1038/s41578-019-0108-1 ↗
16. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery10.1016/j.actbio.2019.02.012 ↗
17. Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy10.1021/acs.nanolett.6b01432 ↗
18. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy10.1038/s41401-020-0400-z ↗
19. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
20. Rational design of cancer nanomedicine–Nanoproperty integration and synchronization
21. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy10.1021/acs.chemrev.5b00148 ↗
22. Carbon dots for in vivo bioimaging and theranostics10.1002/smll.201805087 ↗
23. Evolution and synthesis of carbon dots–From carbon dots to carbonized polymer dots10.1002/advs.201901316 ↗
24. Microenvironment-driven cascaded responsive hybrid carbon dots as a multifunctional theranostic nanoplatform for imaging-traceable gene precise delivery10.1021/acs.chemmater.8b01011 ↗
25. Progress in internal/external stimuli responsive fluorescent carbon nanoparticles for theranostic and sensing applications10.1039/C7TB03323K ↗
26. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy10.1038/s41565-019-0485-z ↗
27. Multifunctional N,S co-doped carbon quantum dots with pH- and thermo-dependent switchable fluorescent properties and highly selective detection of glutathione10.1016/j.carbon.2016.04.003 ↗
28. Resolving the multiple emission centers in carbon dots–From fluorophore molecular states to aromatic domain states and carbon-core states10.1021/acs.jpclett.8b02043 ↗
29. Charge-convertible carbon dots for imaging guided drug delivery with enhanced in vivo cancer therapeutic efficiency10.1021/acsnano.6b00043 ↗
30. Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy
31. The effect of particle design on cellular internalization pathways10.1073/pnas.0801763105 ↗
32. CD44-targeted hyaluronic acid-coated redox-responsive hyperbranched poly(amido amine)/plasmid DNA ternary nanoassemblies for efficient gene delivery10.1021/acs.bioconjchem.6b00240 ↗
33. Effects of Cremophor EL/ethanol/oleinic acid/water microemulsion on human blood components and coagulation function10.1016/j.colsurfb.2019.04.058 ↗
34. Polyethylenimine-induced alterations of red blood cells and their recognition by the complement system and macrophages10.1021/ab500128q ↗
35. Self-sensibilized polymeric prodrug co-delivering MMP-9 shRNA plasmid for combined treatment of tumors10.1016/j.actbio.2018.01.014 ↗
36. mTOR signaling in growth, metabolism, and disease10.1016/j.cell.2017.03.035 ↗
37. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling10.1074/jbc.M803348200 ↗
38. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control10.1016/S1097-2765(02)00636-6 ↗
39. Innate immune recognition of cancer10.1146/annurev-immunol-032414-112043 ↗
40. Dendritic cell SIRT1-HIF1alpha axis programs the differentiation of CD4+ T cells through IL-12 and TGF-beta1
41. Naturally activated Vγ4 γδT cells play a protective role in tumor immunity through expression of eomesodermin10.4049/jimmunol.0903767 ↗
42. ΓδT cells and the lymphoid stress-surveillance response10.1016/j.immuni.2009.08.006 ↗
43. Identification and characterization of latency-associated peptide-expressing γδT cells10.1038/ncomms9726 ↗
44. Natural plant-derived polygalacturonic acid-oleanolic acid assemblies as oral-delivered nanomedicine for insulin resistance treatment
45. Baicalin alleviates lipopolysaccharide-induced liver inflammation in chicken by suppressing TLR4-mediated NF- κB Pathway10.3389/fphar.2017.00547 ↗